

- patients: Determinants of relapse and mortality in a collaborative study of 228 episodes in a Mediterranean region. *Eur J Clin Microbiol Infect Dis*. 2005;24:411–8.
9. Yeşilova Y, Aksoy M, Sürcüçü HA, Uluat A, Ardic N, Yeşilova A. Lip leishmaniasis: Clinical characteristics of 621 patients. *Int J Crit Illn Inj Sci*. 2015;5:265–6.
10. Rouston G, Jiménez JA, Gutiérrez-Solar B, Gallego JL, Alvar J, Patrón M. Post-kala-azar dermal leishmaniasis with mucosal involvement in a kidney transplant recipient: Treatment with liposomal amphotericin B. *Br J Dermatol*. 1998;138:526–8.
11. Marcoval J, Penin RM. Evolution of cutaneous leishmaniasis in the last 30 years in a tertiary hospital of the European Mediterranean coast. *Int J Dermatol*. 2017;56:750–3.

5. Habibi Naderizadeh,^{a,*} C. Valcárcel Sierra,^a
L. Medrano Gallego,^a B.J. Flores Robles,^b
L.G. Roustán-Gullón^c



Bullous Sweet's syndrome with myositis

Síndrome de Sweet ampollar con miositis

Dear Editor:

A 79-year-old female, who had suffered from myelodysplastic syndrome (MDS) (RAEB-1), was referred to our department complaining of painful lesions on the neck, chest and lower extremities with fever-up which appeared three weeks previously. She had received occasional transfusion for her MDS, but granulocyte-colony stimulating factor (G-CSF) was not administered. Physical examination showed ill-defined, tender edematous erythemas with bullous and erosive lesions on the chest (Fig. 1a). In addition, painful fresh-colored erythematous plaques were scattered on the lower extremities. Laboratory examination showed slightly elevated white blood cell counts (9100/ μ l with 27% Band, 29% Seg, 12% Lym, 4% Mono, 4% Eo, 9% Baso, and 10% Meta), and increased levels of erythrocyte sedimentation rate (136 mm/h) and C-reactive protein (9.0 mg/dl). A biopsy specimen from the chest showed dense neutrophilic infiltration throughout the edematous dermis (Fig. 1c). Bacterial culture resulted sterile. Bone marrow biopsy revealed severe hypocellular bone marrow with a marked decrease of erythroblasts and megakaryocytes. After admission, systemic prednisolone (20 mg/day) was started which resulted in the improvement of skin lesions. However, during the course, she complained of severe muscle pain of the right thigh along with fever up to 39°C. Examination by MRI showed edematous swelling on the right gluteus maximus muscle (Fig. 1d). Unfortunately, muscle biopsy was not performed, because her general conditions worsened. Serum creatine kinase level was not elevated and myositis was gradually improved without dose-up of prednisolone. However, her general condition was worsened, and she died of disseminated intravascular coagulation, renal failure, and complete A-V block one month after admission.

^a Servicio de Medicina Familiar y Comunitaria, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, España

^b Servicio de Reumatología, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, España

^c Servicio de Dermatología, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, España

* Corresponding author.

E-mail address: shabnamhab@hotmail.com (S.H. Naderizadeh).

1578-2190/

© 2017 Elsevier España, S.L.U. and AEDV. All rights reserved.

Sweet's syndrome is characterized by tender erythematous skin lesions accompanied by fever-up, in which inflammatory cells predominantly consisted of neutrophils infiltrate diffusely in the dermis. Sometimes Sweet's syndrome presents with atypical variants,¹ and bullous variant is histologically characterized by extensive neutrophilic exocytosis and severe edema of the upper dermis. Whether cases of bullous Sweet's syndrome are commonly associated with hematological disorders is controversial.^{2,3} In the present case, bullous lesions were developed in a patient with active and severe MDS. The patient had no other apparent triggers such as upper airway or gastrointestinal infections and the use of new drugs, for the induction of Sweet's syndrome. Also, the patient developed non-bullous infiltrative erythema on the knee, and muscle tenderness during the course. So far, several cases of extracutaneous manifestations of Sweet's syndrome have been reported involving the lung, digestive tract, joints, lymph nodes, liver, spleen, eyes, central nervous system, and bone.⁴ Only several cases of neutrophilic myositis have been reported in association with neutrophilic dermatosis⁵; however, to our knowledge, there have been no reports of neutrophilic myositis in association with bullous Sweet's syndrome. A previously reported case developed severe sterile neutrophilic myositis as the first manifestation of acute myelogenous leukemia.⁶ In the present case, myositis was developed soon after admission, which occurred almost concurrently with cutaneous manifestations. Because of the increased risk of infection, we did not escalate the dose of prednisolone; however, muscle lesions were transient and gradually improved. Because muscle biopsy was not carried out, it is uncertain that the patient developed neutrophilic myositis during the course. Hematoma was unlikely, but other factor such as infection was not denied, because drainage procedures were not performed. In such cases as immunocompromised patients like ours, it is often difficult to decide whether other organ involvement is caused by aseptic neutrophilic infiltration or infection.




Figure 1 (a) Painful, erosive lesions on the upper chest with peripheral tense blisters (insert). (b) Histological features showing dense neutrophil infiltration throughout the edematous dermis. (c) Higher magnification showed neutrophil infiltration. (d) MRI examination revealed edematous swelling on the right gluteus maximus muscle.

Conflict of interests

The authors declare no conflict of interests.

References

1. Klinger S, Mathis N, Jackson S. Bullous Sweet syndrome associated with an aseptic splenic abscess. *Cutis*. 2009;84:255–8.
2. Mirouse A, Virone A, Gobert D, Soussan M, Braun T, Zioli M, et al. Aseptic muscular abscesses associated with myelodysplastic syndrome. *Eur J Dermatol*. 2014;24:696–7.
3. Cohen PR. Sweet's syndrome: a comprehensive review of an acute febrile neutrophilic dermatosis. *Orphanet J Rare Dis*. 2007;2:34.
4. Wallach D, Vignon-Pennamen MD. From acute febrile neutrophilic dermatosis to neutrophilic disease: forty years of clinical research. *J Am Acad Dermatol*. 2006;55:1066–71.
5. Neoh CY, Tan AWH, Ng SK. Sweet's syndrome: a spectrum of unusual clinical presentations and associations. *Br J Dermatol*. 2007;156:480–5.
6. Marie I, Levesque H, Joly P, Reumont G, Courville P, Baudrimont M, et al. Neutrophilic myositis as an extracutaneous manifestation of neutrophilic dermatosis. *J Am Acad Dermatol*. 2001;44:137–9.

K. Sato, T. Miura, M. Ohtsuka, T. Yamamoto*

Department of Dermatology, Fukushima Medical University, Fukushima, Japan

*Corresponding author.

E-mail address: toyamade@fmu.ac.jp (T. Yamamoto).
1578-2190/

© 2018 Elsevier España, S.L.U. and AEDV. All rights reserved.

Risk of hepatitis B virus reactivation in patients treated with anti-TNF α agents for immune-mediated inflammatory diseases



Riesgo de reactivación de la hepatitis B en los pacientes tratados con agentes anti-TNF α para enfermedades inflamatorias inmuno-mediadas

Dear Editor:

TNF α inhibitors revolutionized the treatment of immune-mediated inflammatory diseases (IMIDs). Due to their immunosuppressive nature, these therapies increase susceptibility for new infections and may alter the natural course of latent infections.^{1,2}

Occult HBV infection is defined as the persistence of viral genome in the liver tissue of individuals serologically negative for HBV surface antigen (HBsAg).³ Patients with positive antibodies to HBV core antigen (anti-HBc) and negative HBsAg and HBV-DNA, with or without antibodies to HBV surface antigen (anti-HBs) are potential occult HBV carriers³ and may reactivate under immunosuppressive therapy.^{1,2} Studies in subjects with past HBV infection treated with anti-TNF α therapy for inflammatory bowel disease (IBD) and

rheumatic diseases estimated a reactivation rate between 1.7% and 5% of patients.^{1,2}

The aim of this retrospective study was to evaluate the rate of reactivation in anti-HBc positive/HBsAg negative patients treated with TNF α inhibitors for psoriasis, rheumatologic diseases and IBD.

Patients treated with TNF α inhibitors for IMIDs from January 2000 to December 2014, for at least one month were retrospectively included. Information regarding patients' HBV screening serology (HBsAg, anti-HBc and anti-HBs antibodies) and HBV-DNA (in anti-HBc positive patients) prior to the initiation of TNF α inhibitors as well as HBsAg seroconversion, HBV-DNA *de novo* detection and ALT/AST levels during anti-TNF therapy were collected. HBV reactivation was defined as titer elevation up to 2–3 times the upper limit of normal ALT, in combination with *de novo* detection of HBV-DNA or HBsAg seroconversion. Furthermore, patients' demographic, clinical and therapeutic characteristics were recorded. This study was approved by the hospital's Institutional Review Board.

From 389 patients treated with TNF α inhibitors during the study period, 26 (9%) patients were anti-HBc positive/HBsAg negative and one patient presented with a serologic profile compatible with chronic hepatitis B. The mean observation time was 43.6 ± 28.7 months. Subjects' demographic and clinical data are reported in [Table 1](#). Nineteen (73.1%) patients were anti-HBs positive in the pre-treatment screening. HBV-DNA levels were available in 7